Constitutional DNA Polymorphisms Associated with the Plasma Imatinib Concentration in Chronic Myeloid Leukemia Patients

Constitutional DNA Polymorphisms Associated with the Plasma Imatinib Concentration in Chronic Myeloid Leukemia Patients

The tyrosine kinase Inhibitor (TKI) imatinib is approved for the treatment of the chronic phase of chronic myeloid leukemia (CP-CML). Pharmacokinetic studies have highlighted the importance of inter-patient variability on imatinib plasma trough concentrations (ima[C]min). In the OPTIM-imatinib trial...

Full description

Saved in:
Bibliographic Details
Main Authors: Heriberto Bruzzoni-Giovanelli (Author), Habib Zouali (Author), Mourad Sahbatou (Author), Benjamin Maneglier (Author), Jean-Michel Cayuela (Author), Angelita Rebollo (Author), Gustavo H. Marin (Author), Daniela Geromin (Author), Carole Tomczak (Author), Antonio Alberdi (Author), Jean-Francois Deleuze (Author), Philippe Rousselot (Author)
Format: Book
Published: MDPI AG, 2024-06-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available

Similar Items